Urovant Sciences Ltd (UROV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 03/31
| 09-2019 | 06-2019 | 03-2019 | 12-2018 | 09-2018 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -54,226 | -28,485 | -111,346 | -82,378 | -55,937 |
| Depreciation Amortization | 113 | 54 | 180 | 132 | 85 |
| Accounts payable and accrued liabilities | -358 | 834 | 1,092 | 2,863 | 3,801 |
| Other Working Capital | 3,960 | 4,198 | -2,202 | -5,760 | 9,616 |
| Other Operating Activity | 3,543 | 894 | 3,240 | 78 | -1,909 |
| Operating Cash Flow | $-46,968 | $-22,505 | $-109,036 | $-85,065 | $-44,344 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -589 | -278 | -593 | -193 | -162 |
| Investing Cash Flow | $-589 | $-278 | $-593 | $-193 | $-162 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 30,000 | N/A | 15,000 | N/A | N/A |
| Common Stock Issued | 220 | 70 | 132,931 | 132,931 | 40,244 |
| Other Financing Activity | -197 | -257 | 40,700 | 41,590 | -1,273 |
| Financing Cash Flow | $30,023 | $-187 | $188,631 | $174,521 | $38,971 |
| Beginning Cash Position | 86,196 | 86,196 | 7,194 | 7,194 | 7,194 |
| End Cash Position | 68,662 | 63,226 | 86,196 | 96,457 | 1,659 |
| Net Cash Flow | $-17,534 | $-22,970 | $79,002 | $89,263 | $-5,535 |
| Free Cash Flow | |||||
| Operating Cash Flow | -46,968 | -22,505 | -109,036 | -85,065 | -44,344 |
| Capital Expenditure | -589 | -278 | -593 | -193 | -162 |
| Free Cash Flow | -47,557 | -22,783 | -109,629 | -85,258 | -44,506 |